Service Revenue was the largest of Adaptive Biotechnologies Corp’s 4 reported lines in fiscal 2025, at $192.83M — 70% of $276.98M.
| Collaborative Arrangement and Arrangement Other than Collaborative | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Service Revenue | $81.14M | $102.74M | $133.03M | $192.83M | |||||
| Collaboration Revenue | $66.39M | $42.58M | $13.45M | $41.28M | |||||
| Sequencing Revenue | — | — | — | — | |||||
| Service & Licensing Revenue | — | $24.96M | — | $23.36M | |||||
| Development Support Revenue | — | — | — | — | |||||
| Development Revenue | — | — | — | — | |||||
| Immune Medicine Service Revenue | $700.00K | — | $20.00M | — | |||||
| Regulatory Milestone Revenue | $6.00M | — | $12.50M | $19.50M | |||||
| Development Revenue Regulatory Milestones | — | — | — | — | |||||
| Total | $154.23M | $170.28M | $178.98M | $276.98M |
In fiscal 2025, which ended December 31, 2025, the 4 revenue lines Adaptive Biotechnologies Corp reported in this breakdown added up to $276.98M. The revenue lines reported changed from fiscal 2024, so the total is not directly comparable with the $178.98M reported that year. Service Revenue was the largest revenue line, at $192.83M or 69.6% of the total, followed by Collaboration Revenue ($41.28M, 14.9%) and Service & Licensing Revenue ($23.36M, 8.4%). Together, the two largest revenue lines made up 84.5% of this total.
Compared with fiscal 2024, Collaboration Revenue grew the fastest, rising 206.9% to $41.28M. Every sizeable revenue line reported in both years grew. Because revenue lines were added or dropped between the two years, part of this reflects how Adaptive Biotechnologies Corp regrouped its reporting.
Service & Licensing Revenue was first reported as a separate revenue line in fiscal 2023. The table also keeps 5 revenue lines that Adaptive Biotechnologies Corp no longer reports, so earlier years can still be read on their original basis; use "Show 5 discontinued" beneath the table to see them. This breakdown covers every fiscal year from 2017 to 2025, as reported in Adaptive Biotechnologies Corp's annual filings.
Mrd Revenue was the largest of Adaptive Biotechnologies Corp’s 3 reported lines in fiscal 2025, at $212.33M — 83% of $254.42M.
| Type Of Arrangement | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2023 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|---|---|---|
| Mrd Revenue | $81.14M | — | — | $102.74M | $145.53M | $212.33M | ||
| Immune Medicine Revenue | $66.39M | — | — | $67.54M | $13.45M | $41.28M | ||
| Genentech Collaboration Agreement | — | $7.70M | $7.70M | — | — | — | ||
| Medicare Reimbursements | $5.20M | — | — | $700.00K | $6.50M | — | ||
| Cancelled Customer Contracts | — | — | — | $600.00K | $1.20M | $800.00K | ||
| Total | $152.73M | $7.70M | $7.70M | $171.58M | $166.68M | $254.42M |
In fiscal 2025, which ended December 31, 2025, the 3 revenue lines Adaptive Biotechnologies Corp reported in this breakdown added up to $254.42M. That is less than the $276.98M in its breakdown by revenue line, so these revenue lines do not account for all of its revenue that year. Mrd Revenue was the largest revenue line, at $212.33M or 83.5% of the total, followed by Immune Medicine Revenue ($41.28M, 16.2%) and Cancelled Customer Contracts ($800.00K, 0.3%). Together, the two largest revenue lines made up 99.7% of this total.
Compared with fiscal 2024, Immune Medicine Revenue grew the fastest, rising 206.9% to $41.28M. Because revenue lines were added or dropped between the two years, part of this reflects how Adaptive Biotechnologies Corp regrouped its reporting.
Cancelled Customer Contracts was first reported as a separate revenue line in fiscal 2023. The table also keeps 2 revenue lines that Adaptive Biotechnologies Corp no longer reports, so earlier years can still be read on their original basis; use "Show 2 discontinued" beneath the table to see them. This breakdown covers 8 fiscal years between 2020 and 2025, as reported in Adaptive Biotechnologies Corp's annual filings.
Adaptive Biotechnologies Corp (ADPT) breaks its revenue down by revenue line. In fiscal 2025, its largest revenue line was Service Revenue, with $192.83M or 69.6% of the total, followed by Collaboration Revenue at $41.28M (14.9%).
Service Revenue was Adaptive Biotechnologies Corp's largest revenue line in fiscal 2025, with $192.83M in revenue, 69.6% of the $276.98M reported across its 4 revenue lines.
Every figure is taken from Adaptive Biotechnologies Corp's annual financial filings and shown as reported: each line keeps the name the company gives it, years follow its own fiscal calendar, and lines it has stopped reporting stay in the table for the years they were reported.
The breakdown by revenue line covers fiscal 2017 to 2025. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.